Capricor Therapeutics, Inc. (CAPR)
8.95
+0.01
(+0.11%)
USD |
NASDAQ |
Oct 02, 16:00
9.02
+0.07
(+0.78%)
After-Hours: 20:00
Capricor Therapeutics Enterprise Value : 373.19M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 373.19M |
| October 01, 2026 | 372.61M |
| September 30, 2026 | 403.40M |
| September 29, 2026 | 351.10M |
| September 28, 2026 | 359.24M |
| September 25, 2026 | 338.90M |
| September 24, 2026 | 351.10M |
| September 23, 2026 | 356.92M |
| September 22, 2026 | 395.85M |
| September 21, 2026 | 370.28M |
| September 18, 2026 | 379.58M |
| September 17, 2026 | 400.50M |
| September 16, 2026 | 350.52M |
| September 15, 2026 | 350.52M |
| September 14, 2026 | 365.05M |
| September 11, 2026 | 339.48M |
| September 10, 2026 | 335.42M |
| September 09, 2026 | 355.17M |
| September 08, 2026 | 379.58M |
| September 04, 2026 | 399.34M |
| September 03, 2026 | 392.36M |
| September 02, 2026 | 427.81M |
| September 01, 2026 | 434.78M |
| August 31, 2026 | 428.97M |
| August 28, 2026 | 410.38M |
| Date | Value |
|---|---|
| August 27, 2026 | 437.69M |
| August 26, 2026 | 397.01M |
| August 25, 2026 | 334.83M |
| August 24, 2026 | 248.25M |
| August 21, 2026 | 218.62M |
| August 20, 2026 | 250.29M |
| August 19, 2026 | 316.82M |
| August 18, 2026 | 264.52M |
| August 17, 2026 | 286.02M |
| August 14, 2026 | 239.54M |
| August 13, 2026 | 97.75M |
| August 12, 2026 | 96.59M |
| August 11, 2026 | 81.48M |
| August 10, 2026 | 76.83M |
| August 07, 2026 | 90.78M |
| August 06, 2026 | 96.01M |
| August 05, 2026 | 81.48M |
| August 04, 2026 | 95.43M |
| August 03, 2026 | 97.17M |
| July 31, 2026 | 76.83M |
| July 30, 2026 | 96.59M |
| July 29, 2026 | 234.89M |
| July 28, 2026 | 234.89M |
| July 27, 2026 | 259.58M |
| July 24, 2026 | 997.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ARS Pharmaceuticals, Inc. | 357.54M |
| SELLAS Life Sciences Group, Inc. | 2.233B |
| Sionna Therapeutics, Inc. | 18.79M |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Cytokinetics, Inc. | 9.205B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.73M |
| Total Expenses (Quarterly) | 40.73M |
| EPS Diluted (Quarterly) | -0.7032 |
| Earnings Yield | -27.37% |
| Normalized Earnings Yield | -27.37 |